We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Allogene Therapeutics (ALLO - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Allogene Therapeutics is a member of our Medical group, which includes 914 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Allogene Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALLO's full-year earnings has moved 9.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ALLO has gained about 49.6% so far this year. Meanwhile, stocks in the Medical group have gained about 2.4% on average. This means that Allogene Therapeutics is performing better than its sector in terms of year-to-date returns.
Brainsway Ltd. Sponsored ADR (BWAY - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 71.6%.
In Brainsway Ltd. Sponsored ADR's case, the consensus EPS estimate for the current year increased 13.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Allogene Therapeutics belongs to the Medical - Biomedical and Genetics industry, a group that includes 439 individual companies and currently sits at #150 in the Zacks Industry Rank. On average, this group has gained an average of 4.8% so far this year, meaning that ALLO is performing better in terms of year-to-date returns.
Brainsway Ltd. Sponsored ADR, however, belongs to the Medical - Products industry. Currently, this 84-stock industry is ranked #146. The industry has moved -14.7% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Allogene Therapeutics and Brainsway Ltd. Sponsored ADR as they could maintain their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Allogene Therapeutics (ALLO - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Allogene Therapeutics is a member of our Medical group, which includes 914 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Allogene Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALLO's full-year earnings has moved 9.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ALLO has gained about 49.6% so far this year. Meanwhile, stocks in the Medical group have gained about 2.4% on average. This means that Allogene Therapeutics is performing better than its sector in terms of year-to-date returns.
Brainsway Ltd. Sponsored ADR (BWAY - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 71.6%.
In Brainsway Ltd. Sponsored ADR's case, the consensus EPS estimate for the current year increased 13.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Allogene Therapeutics belongs to the Medical - Biomedical and Genetics industry, a group that includes 439 individual companies and currently sits at #150 in the Zacks Industry Rank. On average, this group has gained an average of 4.8% so far this year, meaning that ALLO is performing better in terms of year-to-date returns.
Brainsway Ltd. Sponsored ADR, however, belongs to the Medical - Products industry. Currently, this 84-stock industry is ranked #146. The industry has moved -14.7% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Allogene Therapeutics and Brainsway Ltd. Sponsored ADR as they could maintain their solid performance.